SpringWorks Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . SpringWorks Therapeutics
SWTX Stock  USD 34.71  1.61  4.86%   
SpringWorks Therapeutics financial statements provide useful quarterly and yearly information to potential SpringWorks Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on SpringWorks Therapeutics financial statements helps investors assess SpringWorks Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting SpringWorks Therapeutics' valuation are summarized below:
Gross Profit
35 M
Profit Margin
(2.03)
Market Capitalization
2.6 B
Enterprise Value Revenue
24.1353
Revenue
135.5 M
We have found one hundred twenty available fundamental trend indicators for SpringWorks Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of SpringWorks Therapeutics current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.4 B in 2024. Enterprise Value is likely to rise to about 1.3 B in 2024

SpringWorks Therapeutics Total Revenue

5.17 Million

Check SpringWorks Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SpringWorks Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 923.7 K, Selling General Administrative of 207.4 M or Total Revenue of 5.2 M, as well as many indicators such as Price To Sales Ratio of 444, Dividend Yield of 0.0 or PTB Ratio of 3.86. SpringWorks financial statements analysis is a perfect complement when working with SpringWorks Therapeutics Valuation or Volatility modules.
  
Check out the analysis of SpringWorks Therapeutics Correlation against competitors.
For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

SpringWorks Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets762.1 M725.8 M245.6 M
Slightly volatile
Other Current Liabilities68.8 M65.6 M15.8 M
Slightly volatile
Total Current Liabilities82.1 M78.2 M22.6 M
Slightly volatile
Other Liabilities19.6 M18.7 M5.4 M
Slightly volatile
Accounts Payable7.8 M7.4 M3.3 M
Pretty Stable
Cash184.9 M176.1 M75 M
Slightly volatile
Other Assets2.2 M3.7 M1.8 M
Slightly volatile
Short Term Investments318.3 M303.1 M335.4 M
Slightly volatile
Other Current Assets13.3 M12.7 M3.8 M
Slightly volatile
Total Liabilities104.5 M99.6 M37.2 M
Slightly volatile
Intangible Assets13.5 M12.9 M10.8 M
Slightly volatile
Common Stock13.2 K7 K5.3 K
Slightly volatile
Property Plant Equipment14.7 M16.4 M7.2 M
Very volatile
Long Term Debt3 M3.2 M4.2 M
Slightly volatile
Preferred Stock Total Equity3.8 M4.3 M4.7 M
Slightly volatile
Good Will1.5 M1.7 M1.8 M
Slightly volatile
Property Plant And Equipment Net25.3 M24.1 M5.1 M
Slightly volatile
Non Current Assets Total236.1 M224.9 M41.9 M
Slightly volatile
Non Currrent Assets Other2.5 M4.2 M1.3 M
Slightly volatile
Cash And Short Term Investments368 M479.2 M185.4 M
Slightly volatile
Common Stock Shares Outstanding49.5 M63.1 M43.9 M
Slightly volatile
Non Current Liabilities Total13.9 M21.4 M14.9 M
Very volatile
Other Stockholder Equity1.6 B1.5 B328 M
Slightly volatile
Property Plant And Equipment Gross28.1 M26.7 M5.5 M
Slightly volatile
Total Current Assets374.9 M500.9 M189 M
Slightly volatile
Net Working Capital344.6 M422.7 M173.8 M
Slightly volatile
Capital Surpluse477.1 M454.4 M168.1 M
Slightly volatile
Deferred Long Term Liabilities660 K805 K584.3 K
Slightly volatile
Capital Stock6.7 K7 K1.2 M
Slightly volatile
Current Deferred Revenue2.9 M4.1 M1.4 M
Slightly volatile
Common Stock Total Equity5 K5.8 K4.4 K
Slightly volatile
Short Term Debt977.7 K1.1 M579.2 K
Slightly volatile
Short and Long Term Debt Total4.5 M7.1 M3.2 M
Slightly volatile
Capital Lease Obligations4.5 M7.1 M3.2 M
Slightly volatile
Non Current Liabilities Other131.2 K147.6 K160.7 K
Slightly volatile

SpringWorks Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative207.4 M197.6 M46.3 M
Slightly volatile
Research Development158 M150.5 M48.4 M
Slightly volatile
Cost Of Revenue400.9 K422 K4.6 M
Slightly volatile
Interest Income23.3 M22.1 M3.9 M
Slightly volatile
Total Operating Expenses365.4 M348 M95.9 M
Slightly volatile
Net Interest Income23.3 M22.1 M4.2 M
Slightly volatile
Depreciation And Amortization1.8 M1.7 M357.8 K
Slightly volatile
Other Operating Expenses176.3 M348.5 M85.7 M
Slightly volatile
Reconciled Depreciation1.5 M1.4 M319.1 K
Slightly volatile

SpringWorks Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities132.1 K139 K60.9 M
Pretty Stable
Total Cash From Financing Activities311.5 M296.6 M125.2 M
Slightly volatile
Depreciation1.8 M1.7 M353.5 K
Slightly volatile
Change To Operating Activities17.4 M16.5 M4.1 M
Slightly volatile
End Period Cash Flow138.4 M176.7 M72.8 M
Slightly volatile
Change To Netincome93 M88.5 M24.4 M
Slightly volatile
Stock Based Compensation99.3 M94.5 M21.9 M
Slightly volatile
Begin Period Cash Flow129.2 M68.1 M61.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio444423154
Slightly volatile
Days Sales Outstanding318358389
Slightly volatile
Stock Based Compensation To Revenue18.2217.35524.1646
Slightly volatile
Capex To Depreciation4.214.430110.6179
Slightly volatile
EV To Sales412392145
Slightly volatile
Inventory Turnover0.110.120.1332
Slightly volatile
Days Of Inventory On Hand2.1 K2.4 K2.6 K
Slightly volatile
Payables Turnover0.0880.05710.0645
Slightly volatile
Sales General And Administrative To Revenue38.0836.26798.4924
Slightly volatile
Research And Ddevelopement To Revenue14.127.62757.0379
Slightly volatile
Capex To Revenue0.811.35580.379
Slightly volatile
Cash Per Share5.57.59143.6817
Slightly volatile
Interest Coverage294330360
Slightly volatile
Days Payables Outstanding10.3 K6.4 K20.2 K
Slightly volatile
Income Quality0.550.68530.584
Slightly volatile
Intangibles To Total Assets0.01230.01390.0151
Slightly volatile
Net Debt To EBITDA0.470.49512.0443
Slightly volatile
Current Ratio6.096.40815.7193
Pretty Stable
Receivables Turnover0.740.830.9007
Slightly volatile
Graham Number35.633.905611.3349
Slightly volatile
Capex Per Share0.120.1170.0348
Slightly volatile
Revenue Per Share0.0820.08630.6194
Slightly volatile
Debt To Assets0.0020.00150.0022
Slightly volatile
Operating Cycle2.5 K2.8 K3 K
Slightly volatile
Days Of Payables Outstanding10.3 K6.4 K20.2 K
Slightly volatile
Ebt Per Ebit1.080.94780.9943
Pretty Stable
Quick Ratio6.056.368315.714
Pretty Stable
Net Income Per E B T0.780.890.9344
Pretty Stable
Cash Ratio2.142.252212.2103
Slightly volatile
Days Of Inventory Outstanding2.1 K2.4 K2.6 K
Slightly volatile
Days Of Sales Outstanding318358389
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.03311.0095
Slightly volatile
Fixed Asset Turnover0.210.22618.5757
Slightly volatile
Debt Ratio0.0020.00150.0022
Slightly volatile
Price Sales Ratio444423154
Slightly volatile
Asset Turnover0.00710.00750.0468
Slightly volatile
Gross Profit Margin0.960.92250.9437
Slightly volatile

SpringWorks Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 B1.2 B1.3 B
Slightly volatile
Enterprise Value1.3 B1.2 B1.3 B
Slightly volatile

SpringWorks Fundamental Market Drivers

Forward Price Earnings303.0303
Cash And Short Term Investments479.2 M

SpringWorks Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About SpringWorks Therapeutics Financial Statements

SpringWorks Therapeutics investors use historical fundamental indicators, such as SpringWorks Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SpringWorks Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.1 M2.9 M
Total Revenue5.4 M5.2 M
Cost Of Revenue422 K400.9 K
Stock Based Compensation To Revenue 17.36  18.22 
Sales General And Administrative To Revenue 36.27  38.08 
Research And Ddevelopement To Revenue 27.63  14.10 
Capex To Revenue 1.36  0.81 
Revenue Per Share 0.09  0.08 
Ebit Per Revenue(62.97)(66.12)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GMGeneral Motors
MSFTMicrosoft

Additional Tools for SpringWorks Stock Analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY